The BRCT (BRCA1 C Terminus) domain is a protein–protein interaction module found in a diverse set of eukaryotic proteins that participate in DNA repair, cell‑cycle checkpoint control, and signal transduction. First identified in the tumor suppressor protein BRCA1, the BRCT name derives from “BRCA1 C‑terminal” region.
Structure
BRCT domains are typically composed of ~90–100 amino acids that fold into a conserved globular structure consisting of a central β‑sandwich flanked by α‑helices. Many BRCT-containing proteins possess tandem copies of the domain (BRCT1 and BRCT2) that together form a phosphopeptide‑binding pocket. High‑resolution X‑ray crystallography and NMR studies have revealed that the tandem arrangement creates a cleft that specifically recognizes phosphorylated serine or threonine residues within defined sequence motifs (e.g., pSer‑X‑X‑Phe).
Functional characteristics
| Feature | Description |
|---|---|
| Ligand specificity | Primarily binds phosphorylated peptide motifs, often generated by checkpoint kinases such as ATM, ATR, and Chk2. |
| Cellular processes | Mediates recruitment of DNA‑damage response factors to sites of double‑strand breaks, regulates homologous recombination, and contributes to G2/M checkpoint enforcement. |
| Protein families | Found in BRCA1, BRCA2, TOPBP1, 53BP1, RBBP1, MDC1, and several checkpoint kinases (e.g., CHK2). |
| Evolutionary conservation | Present across metazoans and conserved in many plant and fungal proteins, indicating an ancient role in genome maintenance. |
Biological significance
- DNA‑damage response (DDR): In BRCA1, the tandem BRCT domains recognize phosphorylated histone H2AX (γ‑H2AX) and other DDR proteins, facilitating assembly of repair complexes at damaged chromatin.
- Tumor suppression: Mutations that disrupt BRCT folding or phosphopeptide binding abolish BRCA1’s tumor‑suppressor activity and are linked to hereditary breast and ovarian cancers.
- Checkpoint signaling: TOPBP1’s BRCT domains interact with phosphorylated RAD9, integrating signals that activate the ATR checkpoint pathway during replication stress.
Pathogenic variants
Numerous pathogenic missense mutations in the BRCT region of BRCA1 (e.g., C61G, M1775R) have been catalogued in clinical databases such as ClinVar. These variants typically impair phosphopeptide binding, destabilize the domain, or prevent proper protein localization, thereby compromising DNA‑repair fidelity.
Research and therapeutic implications
- Structural studies: Detailed crystal structures have guided the design of small molecules that mimic phosphopeptide ligands, aiming to modulate BRCT-mediated interactions.
- Biomarker potential: The presence or loss of functional BRCT domains in tumor samples can inform prognosis and guide the use of PARP inhibitors in BRCA‑mutated cancers.
References (representative)
- Williams, R. S., et al. (2004). “Structural basis for phosphopeptide recognition by the BRCT domains of BRCA1.” Nature Structural & Molecular Biology, 11(8), 715–721.
- Yu, X., & Chen, J. (2006). “The BRCT domain: a phospho‑protein binding module involved in DNA repair and cell‑cycle checkpoint control.” Oncogene, 25(28), 3825–3832.
- Venkitaraman, A. R. (2002). “Cancer susceptibility and the functions of BRCA1 and BRCA2.” Cell, 108(2), 171–182.
The above information reflects the current consensus in peer‑reviewed literature as of 2024.